Literature DB >> 26682502

Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.

Yang Zhao1, Wei Ren1, Ting Zhong1, Shuang Zhang1, Dan Huang1, Yang Guo1, Xin Yao1, Chao Wang1, Wei-Qiang Zhang1, Xuan Zhang2, Qiang Zhang3.   

Abstract

The pH environment in gliomas is acidic. Therefore, in the present research, we selected our previously reported tumor-specific pH-responsive peptide H7K(R2)2 as a targeting ligand, which could respond to the acidic pH environment in gliomas, possessing CPP characteristics. The pH-sensitive liposomes were selected as carriers which could also respond to the acidic pH environment in gliomas triggering encapsulated drug release from these pH-sensitive liposomes. The H7K(R2)2-modified pH-sensitive liposomes containing doxorubicin (DOX-PSL-H7K(R2)2) were designed and prepared in order to evaluate their potential targeting of glioma tumor cells and their anti-tumor activity in mice with glioma tumor cells. DOX-PSL-H7K(R2)2 was prepared by the thin-film hydration method followed by remote loading using an ammonium sulfate gradient method. The in vitro release of DOX from pH-sensitive liposomes was tested and the in vitro targeting characteristics of H7K(R2)2-modified liposomes regarding C6 (rat C6 glioma cells) and U87-MG (human glioblastoma cells) were evaluated. The in vivo anti-tumor activity of DOX-PSL-H7K(R2)2 was also investigated in C6 tumor-bearing mice and in U87-MG orthotopic tumor-bearing nude mice. A specific targeting effect triggered by an acidic pH was observed in our in vitro experiments in C6 and U87-MG glioma cells. The pH-triggered DOX release from the pH-sensitive liposomes under acidic conditions was also confirmed in our in vitro experiment. Anti-tumor activity of DOX-PSL-H7K(R2)2 was found in C6 tumor-bearing mice and U87-MG orthotopic tumor-bearing nude mice in in vivo experiments. The antiangiogenic activity of DOX-PSL-H7K(R2)2 was confirmed in C6 tumor-bearing mice in the in vivo experiment. These H7K(R2)2-modified pH-sensitive liposomes containing anti-tumor drugs developed in this study are a promising delivery system involving the response stimuli at the acidic pH in the glioma tumor microenvironment and are suitable for anti-tumor therapy.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-tumor activity; Glioma; Targeting; Tumor-specific pH-responsive peptide; pH-sensitive liposomes

Mesh:

Substances:

Year:  2015        PMID: 26682502     DOI: 10.1016/j.jconrel.2015.12.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  41 in total

1.  Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.

Authors:  Parham Sahandi Zangabad; Soroush Mirkiani; Shayan Shahsavari; Behrad Masoudi; Maryam Masroor; Hamid Hamed; Zahra Jafari; Yasamin Davatgaran Taghipour; Hura Hashemi; Mahdi Karimi; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2017-12-12       Impact factor: 7.848

Review 2.  Stimuli-responsive liposomes for drug delivery.

Authors:  Y Lee; D H Thompson
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-15

Review 3.  Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting.

Authors:  Muhammad Abdur Rahim; Nasrullah Jan; Safiullah Khan; Hassan Shah; Asadullah Madni; Arshad Khan; Abdul Jabar; Shahzeb Khan; Abdelbary Elhissi; Zahid Hussain; Heather C Aziz; Muhammad Sohail; Mirazam Khan; Hnin Ei Thu
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

4.  Chitosan-Coated Liposomes: The Strategy to Reduce Intestinal Toxicity and Improve Bioavailability of Oral Vinorelbine.

Authors:  Chen Guo; Xichun Zhu; Haoyang Yuan; Haoyu Liu; Yu Zhang; Tian Yin; Haibing He; Jingxin Gou; Xing Tang
Journal:  AAPS PharmSciTech       Date:  2022-06-10       Impact factor: 3.246

Review 5.  Strategies for Liposome Drug Delivery Systems to Improve Tumor Treatment Efficacy.

Authors:  Jia Wang; Junbo Gong; Zhenping Wei
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

6.  A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer.

Authors:  Jafrin Jobayer Sonju; Achyut Dahal; Sitanshu S Singh; Xin Gu; William D Johnson; Chandra Mohan Reddy Muthumula; Sharon A Meyer; Seetharama D Jois
Journal:  Int J Pharm       Date:  2021-12-09       Impact factor: 6.510

Review 7.  Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment.

Authors:  Jafrin Jobayer Sonju; Achyut Dahal; Sitanshu S Singh; Seetharama D Jois
Journal:  J Control Release       Date:  2020-10-01       Impact factor: 9.776

Review 8.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

Review 9.  Dual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment.

Authors:  Nour AlSawaftah; William G Pitt; Ghaleb A Husseini
Journal:  ACS Pharmacol Transl Sci       Date:  2021-06-01

10.  Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA.

Authors:  Xinlong Zang; Huaiwei Ding; Xiufeng Zhao; Xiaowei Li; Zhouqi Du; Haiyang Hu; Mingxi Qiao; Dawei Chen; Yuihui Deng; Xiuli Zhao
Journal:  Int J Nanomedicine       Date:  2016-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.